BBIO BridgeBio Pharma Inc.

Drug Information

Drug catalyst information is displayed when you hover over / tap on the stage bar graph.

Latest News

1. 13 January 2020 BridgeBio Pharma Grows Pipeline to 20+ Genetic Medicines with Four Assets Focused on Treating Genetically Driven Diseases at Their Source

   SAN FRANCISCO, Jan. 13, 2020 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (NASDAQ:BBIO) today disclosed four additional assets in its pipeline, expanding the number of disclosed programs to over 20 potential medicines.

2. 10 January 2020 BridgeBio Pharma's Gene Therapy Subsidiaries Enter Strategic Partnership with Catalent for Dedicated Gene Therapy Development and Manufacturing Capacity

   The deal is designed to accelerate BridgeBio's gene therapy programsThe dedicated suite will support clinical and commercial supply needs for BridgeBio's gene therapy programs for congenital adrenal hyperplasia (BBP-631)

3. 08 January 2020 PellePharm Initiates Phase 2 Clinical Trial of Patidegib Topical Gel for People With High Frequency Basal Cell Carcinoma

   PellePharm, Inc., a BridgeBio Pharma, Inc. (NASDAQ:BBIO) company, today announced it has dosed the first two participants in a Phase 2 clinical trial of Patidegib Topical Gel, 2%, vs. vehicle gel for people with

4. 06 January 2020 BridgeBio Pharma's QED Therapeutics Receives Fast Track Designation for Infigratinib in Adults with First-Line Advanced or Metastatic Cholangiocarcinoma and Orphan Drug Designation for Infigratinib for Treatment of Cholangiocarcinoma

   SAN FRANCISCO, Jan. 06, 2020 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (NASDAQ:BBIO) subsidiary QED Therapeutics announced today that it has secured both Fast Track Designation in adults with first-line advanced or

5. 19 December 2019 BridgeBio Pharma, Inc. to Present at Upcoming Investor Conference

   PALO ALTO, Calif., Dec. 19, 2019 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (NASDAQ:BBIO) announced today that it will present at the 38th Annual J.P. Morgan Healthcare Conference on Monday, January 13, 2020 at 3 PM

6. 18 December 2019 BridgeBio Pharma's Origin Biosciences Enters Partnership With Medison to Commercialize BBP-870 in Israel for MoCD Type A

   BOSTON, Dec. 18, 2019 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (NASDAQ:BBIO) subsidiary Origin Biosciences, a company focused on developing and commercializing a treatment for Molybdenum Cofactor Deficiency (MoCD)

7. 16 December 2019 BridgeBio Pharma, Inc. Appoints Industry Leader Jennifer Cook as New Board Member

   PALO ALTO, Calif., Dec. 16, 2019 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (NASDAQ:BBIO) today announced it has appointed Jennifer Cook to its Board of Directors and will leverage her considerable expertise as a

8. 09 December 2019 BridgeBio Pharma, Inc. Appoints Eli Wallace as Chief Scientific Officer in Residence for Oncology Programs

   PALO ALTO, Calif., Dec. 09, 2019 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (NASDAQ:BBIO), a clinical-stage biopharmaceutical company focused on genetic diseases, announced it has appointed Eli Wallace, Ph.D., as its

9. 05 December 2019 BridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

   PALO ALTO, Calif., Dec. 05, 2019 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (NASDAQ:BBIO), a clinical-stage biopharmaceutical company focused on genetic diseases, today announced that on November 22, 2019, the

10. 03 December 2019 BridgeBio Pharma's Origin Biosciences Initiates Rolling Submission of New Drug Application with the U.S. FDA for BBP-870 for the Treatment of MoCD Type A

    BOSTON, Dec. 03, 2019 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (NASDAQ:BBIO) subsidiary Origin Biosciences has initiated a rolling submission of a New Drug Application (NDA) with the United States Food and Drug

11. 02 December 2019 PellePharm Completes Enrollment of Pivotal Phase 3 Clinical Trial of Patidegib Topical Gel in Patients with Gorlin Syndrome

    - Trial rapidly enrolled in 8 months - Trial size expanded to accommodate 24 more patients than planned PellePharm, Inc., a BridgeBio Pharma, Inc. (NASDAQ:BBIO) company, today announced the completion of enrollment

12. 27 November 2019 BridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

    PALO ALTO, Calif., Nov. 27, 2019 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (NASDAQ:BBIO), a clinical-stage biopharmaceutical company focused on genetic diseases, today announced grants of inducement awards to its

13. 16 November 2019 BridgeBio and Eidos Present Data from Phase 2 Open Label Extension Suggesting Long-term Tolerability of AG10 and Stabilization of Transthyretin Amyloid Cardiomyopathy Disease Measures

    AG10 was Well Tolerated with Median 65 Weeks Follow-up since Phase 2 Initiation Rates of All-Cause Mortality (Including Either Death or Cardiac Transplantation, 8.5%) and Cardiovascular Hospitalization (25.5%)

14. 07 November 2019 BridgeBio Pharma Reports Third Quarter 2019 Financial Results and Highlights Portfolio Progress

    Multiple clinical and pre-clinical milestones achieved across the BridgeBio portfolioDelivered pipeline growth with the addition of BBP-418 for limb-girdle muscular dystrophy type 2iEnded quarter with $446.1 million in

15. 31 October 2019 Eidos Therapeutics Reports Third Quarter 2019 Financial Results and Business Update

    SAN FRANCISCO, Oct. 31, 2019 (GLOBE NEWSWIRE) -- Eidos Therapeutics, Inc. (Eidos) (NASDAQ:EIDX), a subsidiary of BridgeBio Pharma, Inc. (BridgeBio) (NASDAQ:BBIO), today reported its financial results for the third

16. 14 October 2019 BridgeBio Pharma Terminates Merger Process With Its Subsidiary Eidos Therapeutics

    Agreement Not Reached Between BridgeBio Pharma and Special Committee of Eidos Therapeutics Independent Directors; BridgeBio No Longer Pursuing Acquisition BridgeBio Pharma, Inc. (NASDAQ:BBIO), a clinical-stage

17. 24 September 2019 Ivy Brain Tumor Center and BridgeBio Subsidiary QED Therapeutics Announce Collaboration to Advance Cancer Research and Treatment Options

    PHOENIX, Sept. 24, 2019 (GLOBE NEWSWIRE) -- The Ivy Brain Tumor Center at Barrow Neurological Institute, today announced a new collaboration with QED Therapeutics, Inc., a subsidiary of BridgeBio Pharma,